WO2002002500A1 - Preparation of (r)-2-alkyl-3-phenylpropionic acids - Google Patents

Preparation of (r)-2-alkyl-3-phenylpropionic acids Download PDF

Info

Publication number
WO2002002500A1
WO2002002500A1 PCT/CH2001/000397 CH0100397W WO0202500A1 WO 2002002500 A1 WO2002002500 A1 WO 2002002500A1 CH 0100397 W CH0100397 W CH 0100397W WO 0202500 A1 WO0202500 A1 WO 0202500A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
alkyl
process according
methoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CH2001/000397
Other languages
English (en)
French (fr)
Inventor
Peter Herold
Stefan Stutz
Felix Spindler
Thomas Sturm
Walter Weissensteiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Speedel Pharma AG
Original Assignee
Speedel Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Pharma AG filed Critical Speedel Pharma AG
Priority to AT01940045T priority Critical patent/ATE546425T1/de
Priority to JP2002507758A priority patent/JP2004502663A/ja
Priority to CA2414839A priority patent/CA2414839C/en
Priority to EP01940045A priority patent/EP1296927B1/en
Priority to AU2001273761A priority patent/AU2001273761A1/en
Priority to US10/312,855 priority patent/US6683206B2/en
Priority to BR0112146-4A priority patent/BR0112146A/pt
Publication of WO2002002500A1 publication Critical patent/WO2002002500A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/36Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds

Definitions

  • the invention relates to a stereoselective process for the preparation of (R) -2-alkyl-3-phenyl-propionic acids and intermediate products obtained in the process steps.
  • EP-A-0 -678 503 ⁇ -amino- ⁇ -hydroxy- ⁇ -aryl-alkanecarbox- amides are described which exhibit renin-inhibiting properties and could be used as antihypertensive agents in pharmaceutical preparations.
  • the manufacturing processes described are unsatisfactory in terms of the number of process steps and yields and are not suitable for an industrial process.
  • a disadvantage of these processes is also that the total yields of pure diastereomers that are obtainable are too small.
  • the 2, 7-dialkyl-8-aryl-4-octenoyl amides may correspond for example to formula A,
  • R x and R 2 are, independently of one another, H, C ⁇ -C 6 alkyl , d-C 6 halogenalkyl , C ⁇ C 6 alkoxy, C ⁇ -C 3 alkoxy-C ⁇ - C 6 alkyl , or C ⁇ -C 6 alkoxy-C ⁇ -C 6 alkyloxy, R 3 is C ⁇ -C 6 alkyl, R is C ⁇ -C 6 alkyl , R 6 is C ⁇ -C 6 alkyl , R 5 is C ⁇ C 6 alkyl or C ⁇ -C 6 alkoxy, or R 5 and R 6 together are tetramethylene, pentamethylene, 3-oxa-l , 5-pentylene or -CH 2 CH 2 0-C (0) - substituted if necessary with C ⁇ -C 4 alkyl , phenyl or benzyl .
  • Ri to R 4 , R 5 and R ⁇ are as defined above, Y is-Cl, Br or I and Z is Cl, Br or I, in the presence of an alkali metal or alkaline earth metal. Y and Z are preferably Br and especially Cl .
  • the compounds of formula B are known from EP-A-0 678 503.
  • the compounds of formula C may be prepared from amidation of the corresponding carbonic esters, amides, or halides.
  • the formation of carboxamides from carbonic esters and amines in the presence of trialkyl aluminium or dialkyl aluminium halide, for example using trimethyl aluminium or dimethyl aluminium chloride, is described by S. M. einreb in Org. Synthesis, VI, page 49 (1988) .
  • the carbonic esters are obtainable by the reaction of trans-1, 3-dihalogenpropene (for example, trans-1, 3-dichlorepropene) with corresponding carbonic esters in the presence of strong bases, for example alkali metal amides.
  • the carboxylic acids obtained after saponification can in turn be surprisingly hydrogenated in the presence of homogeneous, asymmetric hydrogenation catalysts to form practically enantiomer-pure 2-alkyl-3-phenylpropionic acids. These acids can then be reduced in a manner known per se to form enantiomer-pure alcohols, from which the compounds of formula B are obtainable by halogenation.
  • the object of the invention is a process for the preparation of"compounds of formula I,
  • Ri and R 2 are, independently of one another, H, Ci- C 6 alkyl, C ⁇ -C 6 halogenalkyl, C ⁇ C 6 alkoxy, C ⁇ -C 6 alkoxy-C ⁇ -C 6 - alkyl , or C ⁇ -C 6 alkoxy-C ⁇ -C 6 alkyloxy, and R 3 is C ⁇ -C 6 alkyl , comprising a) the reaction of a compound of formula I I
  • R 7 is C ⁇ -C ⁇ 2 alkyl, C 3 -C 8 cycloalkyl, phenyl or benzyl, b) the isolation of the crystalline compound of formula IV, the conversion of the OH group to a leaving group, and the reaction of a compound containing a leaving group in the presence of a strong base to form a compound of formula V,
  • Ri and R 2 may be a linear or branched alkyl and preferably comprise 1 to 4 C atoms. Examples are methyl, ethyl, n- and i-propyl, n-, i- and t-butyl, pentyl and hexyl .
  • Ri and R 2 may be a linear or branched halogenalkyl and preferably comprise 1 to 4 C atoms, 1 or 2 C atoms being especially preferred. Examples are fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloro- methyl, trichloromethyl, 2-chloroethyl and 2, 2, 2-trifluoro- ethyl . Ri and R 2 may be a linear or branched alkoxy and preferably comprise 1 to 4 C atoms. Examples are methoxy, ethoxy, n- and i-propyloxy, n-, i- and t-butyloxy, pentyloxy and hexyloxy.
  • Ri and R 2 may be a linear or branched alkoxyalkyl.
  • the alkoxy group preferably comprises 1 to 4 and especially 1 or 2 C atoms
  • the alkyl group preferably comprises 1 to 4 C atoms. Examples are methoxymethyl, l-methoxyeth-2-yl, l-methoxyprop-3-yl, l-methoxybut-4-yl, methoxypentyl, methoxyhexyl, ethoxymethyl, l-ethoxyeth-2-yl, 1-ethoxyprop- 3-yl, l-ethoxybut-4-yl, ethoxypentyl, ethoxyhexyl, propyloxymethyl, butyloxymethyl, l-propyloxyeth-2-yl and l-butyloxyeth-2-yl .
  • Ri and R 2 may be linear or branched C ⁇ -C 6 alkoxy-C ⁇ -C 6 alkylox .
  • the alkoxy group preferably comprises 1 to 4 and especially 1 or 2 C atoms, and the alkyloxy group preferably comprises 1 to 4 C atoms.
  • Examples are methoxymethyloxy, 1-methoxyeth- 2-yloxy, l-methoxyprop-3-yloxy, l-methoxybut-4-yloxy, methoxypentyloxy, methoxyhexyloxy, ethoxymethyloxy, l-ethoxyeth-2-yloxy, l-ethoxyprop-3-yloxy, l-ethoxybut-4- yloxy, ethoxypentyloxy, ethoxyhexyloxy, propyloxymethyloxy, butyloxy ethyloxy, l-propyloxyeth-2-yloxy and 1-butyloxyeth- 2-yloxy.
  • Ri is methoxy-C ⁇ -Calkyloxy or ethoxy-C ⁇ -C 4 alkyloxy, and R 2 is preferably methoxy or ethoxy. Quite especially preferred are compounds of formula I, wherein Ri is l-methoxyprop-3-yloxy and R 2 is methoxy.
  • R 3 may be a linear or branched alkyl and preferably comprise 1 to 4 C atoms. Examples are methyl, ethyl, n- and i-propyl, n-, i- and t-butyl, pentyl and hexyl .
  • R 3 in compounds of formula I is isopropyl.
  • Ri is methoxy-n-propoxy
  • R 2 is methoxy
  • R 3 is isopropyl.
  • R 7 is preferably C ⁇ -C 6 alkyl, C ⁇ -C 4 alkyl being especially preferred; some examples are methyl, ethyl, n-propyl and n- butyl.
  • the starting compounds of formulae II and III used in process step a) are known or can be prepared in a manner similar to known processes.
  • Compounds of formula II are described in EP-A 0 678 503.
  • the reaction is advantageously carried out at low temperatures, for example 0-40°C, in the presence of at least equivalent quantities of strong bases.
  • the reaction is further expediently carried out in a solvent, ethers such as diethyl ether, tetrahydrofuran and dioxane being especially suitable.
  • Suitable strong bases are in particular alkali metal alcoholates and secondary amides, such as lithium diisopropylamide.
  • the desired diastereomer of formula IV is surprisingly formed up to about 75%.
  • the compounds of formula IV are surprisingly crystalline and can therefore be readily isolated without any substantial losses by means of extraction and crystallization.
  • the conversion of the OH group to a leaving group in reaction step b) is known per se.
  • Reaction with carboxylic acids or sulfonic acids, or their anhydrides (acylation) is especially suitable.
  • carboxylic acids are formic acid, acetic acid, propionic acid, benzoic acid, benzenesulfonic acid, toluenesulfonic acid, methylsulfonic acid and trifluoromethylsulfonic acid.
  • acetic acid anhydride has proved especially successful.
  • the elimination is expediently carried out in the presence of strong bases, alkali metal alcoholates such as potassium t- butylate being especially suitable.
  • solvents such as ethers is expedient.
  • the reaction is advantageously carried out at low temperatures, for example 0-40°C. It is of advantage to conduct the elimination reaction directly in the reaction mixture for acylation.
  • the elimination leads to the desired Z iso ers with surprisingly high regioselectivity.
  • These isomers are crystalline and can therefore be readily isolated without any substantial losses by means of extraction and crystallization. The yields are above 80%.
  • Hydrolysis of the ester of formula V to form the carboxylic acids of formula VI in process step c) is a generally known reaction.
  • the hydrolysis may be carried out after isolation and purification of the compound of formula III. It is expedient to add water to the reaction mixture of process step b) , to evaporate off the solvent and then to carry out alkaline or acidic hydrolysis.
  • the carboxylic acids of formula VI are crystalline and can be readily isolated in yields of 80% or more.
  • the skeletal structures of the chiral ditertiary diphosphines may be acyclic, monocyclic or polycyclic.
  • the phosphine groups may be substituted with the same or with different, preferably the same, substituents selected from the group of C ⁇ -C 8 alkyl, C 3 -C 8 cycloalkyl, C 6 - C 12 aryl, and C 6 -C ⁇ aryl- C ⁇ -C 4 alkyl. Cycloalkyl and aryl may be unsubstituted or substituted with C ⁇ -C 4 alkyl, C ⁇ -C 4 alkoxy, C ⁇ -C 4 fluoroalkyl or C-C ⁇ 2 secondary a ino.
  • Suitable phosphine groups are also phosphanyl, preferably five-member phosphanyl, which if necessary is substituted in one or both ⁇ -positions with C ⁇ C 4 alkyl or C ⁇ C 4 alkoxy.
  • Me is rhodium
  • Y stands for two olefins or one diene
  • Z is Cl, Br or I
  • E ⁇ is the anion of an oxygen acid or a complex acid
  • L is a chiral ligand from the group of ditertiary diphosphines, in which the phosphine groups are bonded to a C 2 -C chain of the diphosphine backbone chain, and the diphosphine forms a five to seven-member ring together with the rhodium atom.
  • Y stands for two olefins, they may be C 2 -C ⁇ 2 olefins, C 2 -C 6 olefins being preferred and C 2 -C 4 olefins being especially preferred.
  • Examples are propene, but-1-ene and especially ethylene.
  • the diene may comprise 5 to 12 and preferably 5 to 8 C atoms and may be an acyclic, cyclic or polycyclic diene.
  • the two olefin groups of the diene are preferably linked by one or two CH 2 groups.
  • Examples are 1, 3-pentadiene, cyclopentadiene, 1, 5-hexadiene, 1, 4-cyclohexadiene, 1,4- or 1, 5-heptadiene, 1,4- or 1, 5-cycloheptadiene, 1,4- or 1,5- octadiene, 1,4- or 1, 5-cyclooctadiene and norbornadiene.
  • Y represents preferably two ethylene or 1,5- hexadiene, 1,5- cyclooctadiene or norbornadiene.
  • Z is preferably Cl or Br.
  • Examples of Ei are C10 4 " , CF 3 S0 3 “ , CH 3 S0 3 “ , HS0 4 ⁇ , BF 4 " , B(phenyl) 4 “ , PF 6 “ , SbCl 6 “ , AsF 6 “ or SbF 6 “ .
  • n is 0 or an integer from 1 to 4 and R' represents the same or different substituents selected from the C ⁇ -C 4 alkyl, -CF 3 and C ⁇ -Calkoxy group; and Xi and X 2 are, independently of one another, secondary phosphino.
  • R' may preferably comprise 1 to 2 C atoms. Linear alkyl is preferred. Examples of R' as an alkyl are methyl, ethyl, n- and i-propyl, n-, i- and t-butyl. Methyl and ethyl are preferred, and methyl is especially preferred.
  • R' may .preferably comprise 1 to 2 C atoms. Linear alkoxy is preferred.
  • Examples of R' as an alkoxyl are methoxy, ethoxy, n- and i-propoxy, n-, i- and t-butoxy. Methoxy and ethoxy are preferred and methoxy is especially preferred.
  • the Xi and X 2 groups may be different or preferably the same and correspond to formula PR 8 Rs > , wherein R 8 and R 9 are the same or different and represent branched C 3 -C 8 alkyl, C 3 - C 8 cycloalkyl, or unsubstituted or phenyl substituted with one to three C ⁇ -C 4 alkyl, C ⁇ -C-alkoxy, or -CF 3 .
  • ligands of formulae VIII and Villa wherein n is 0, and Xi and X 2 are a PR 8 R 9 group, wherein R 8 and R 9 in each case are cyclohexyl, phenyl or phenyl substituted with 1 or 2 methyl, methoxy or CF 3 .
  • the new ligands are prepared by means of reactions that are known per se or analogous to known reactions, such as those described in US-A-5, 371, 256, US-A-5, 446, 844 and US-A- 5,583,241.
  • Ligands with other phosphine groups may be prepared in a manner analogous to the method described in the example.
  • the metal complexes used as catalysts may be added as separately prepared isolated compounds, or also formed in situ before the reaction and then mixed with the substrate to be hydrogenated. It may be advantageous in the reaction using isolated metal complexes to add additional ligands, or in the in situ preparation to use surplus ligands.
  • the surplus may for example be up to 10 moles and preferably 0.001 to 5 moles, based on the metal complexes used for the preparation.
  • Process step d) may be carried out at low or elevated temperatures, for example at temperatures from -20 to 150°C, preferably from -10 to 100°C, temperatures of 10 to 80°C being especially preferred.
  • the optical yields are generally better at low temperatures than at high temperatures.
  • the process according to the invention may be carried out at normal pressure or preferably under positive pressure.
  • the pressure may for example range from 10 5 to 2xl0 7 Pa (Pascal) .
  • Catalysts are preferably used in quantities from 0.0001 to 10 mol-% based on the compound to be hydrogenated, the range
  • catalysts as well as process step d) and the other process steps may be carried out in the absence or the presence of an inert solvent, wherein one solvent or a mixture of solvents may be used.
  • Suitable solvents are, for example, aliphatic, cycloaliphatic and aromatic hydrocarbons
  • the reaction may be carried out in the presence of co- catalysts, for example quaternary ammonium halogenides (tetrabutylammonium iodide) and/or in the presence of protonic acids, for example mineral acids.
  • co- catalysts for example quaternary ammonium halogenides (tetrabutylammonium iodide) and/or in the presence of protonic acids, for example mineral acids.
  • the intermediate products of formula (B) may be prepared via all process steps in yields of at least 50% by weight, based on the compounds of formula II.
  • the high total yields make the process suitable for industrial use.
  • a further object of the invention relates to the compounds (intermediates) of formula IX,
  • Ri, R 2 and R 3 are as defined hereinbefore and X is the -COOH group.
  • a solution of 436 ml diisopropylamine and 2.6 1 tetrahydrofuran is cooled to -20°C, and 1.234 1 n-hexyl lithium (2.5 M in hexane) is added dropwise over a period of 15 minutes.
  • a solution of 368 g ethyl isovalerate in 1.7 1 tetrahydrofuran is added dropwise over a period of 15 minutes at -20°C.
  • a solution of 584 g 4-methoxy-3- (3-methoxy-propoxy) benzaldehyde EP 0 678 503 in 1.7 1 tetrahydrofuran is added drop by drop and stirred for 40 minutes at -20°C.
  • the solution is forced under pressure via a steel capillary tube into a 300 ml steel autoclave under cover of argon.
  • argon 20 bar / hydrogen 20 bar the hydrogen pressure is eventually increased to 50 bar.
  • Hydrogenation is started by switching on the stirrer and carried out at room temperature. The reaction takes place via hydrogen consumption (fall of pressure in the reservoir of hydrogen) . After a reaction time of 8 hours, a full conversion is measured by HPLC (method 1) .
  • the solution is forced under pressure via a steel capillary tube into a 50 ml steel autoclave under cover of argon.
  • argon 20 bar / hydrogen 20 bar the hydrogen pressure is eventually increased to 20 bar.
  • Hydrogenation is started by switching on the stirrer and carried out at room temperature. The reaction takes place via hydrogen consumption (fall of pressure in the reservoir of hydrogen) . After a reaction time of 20 hours, a full conversion is measured.
  • the optical yield amounts to >95% (R) -compound.
  • Bl and B2 are derivatized (preparation of the respective methyl esters) : a sample of the residue in diethyl ether is mixed with excess diazo methane in diethyl ether. The solvent is then evaporated off, and the residue obtained is the corresponding methyl ester.
  • Method 1 determination of conversion
  • Method 2 determination of optical yield: column: Daicel OJ-R 0.45 x 15 cm; solvent 30% acetonitrile and 70% water.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/CH2001/000397 2000-07-03 2001-06-26 Preparation of (r)-2-alkyl-3-phenylpropionic acids Ceased WO2002002500A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT01940045T ATE546425T1 (de) 2000-07-03 2001-06-26 Herstellung von (r)-2-alkyl-3-phenylpropionsäuren
JP2002507758A JP2004502663A (ja) 2000-07-03 2001-06-26 (r)−2−アルキル−3−フェニルプロピオン酸の調製
CA2414839A CA2414839C (en) 2000-07-03 2001-06-26 Preparation of (r)-2-alkyl-3-phenylpropionic acids
EP01940045A EP1296927B1 (en) 2000-07-03 2001-06-26 Preparation of (r)-2-alkyl-3-phenylpropionic acids
AU2001273761A AU2001273761A1 (en) 2000-07-03 2001-06-26 Preparation of (r)-2-alkyl-3-phenylpropionic acids
US10/312,855 US6683206B2 (en) 2000-07-03 2001-06-26 Preparation of (R -2-alkyl-3-phenylpropionic acids
BR0112146-4A BR0112146A (pt) 2000-07-03 2001-06-26 Preparação de ácidos (r)-2-alquil-3-fenilpropiÈnicos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH13172000 2000-07-03
CH1317/00 2000-07-03

Publications (1)

Publication Number Publication Date
WO2002002500A1 true WO2002002500A1 (en) 2002-01-10

Family

ID=4565374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2001/000397 Ceased WO2002002500A1 (en) 2000-07-03 2001-06-26 Preparation of (r)-2-alkyl-3-phenylpropionic acids

Country Status (11)

Country Link
US (1) US6683206B2 (enExample)
EP (1) EP1296927B1 (enExample)
JP (1) JP2004502663A (enExample)
CN (1) CN100482632C (enExample)
AR (1) AR028783A1 (enExample)
AT (1) ATE546425T1 (enExample)
AU (1) AU2001273761A1 (enExample)
BR (1) BR0112146A (enExample)
CA (1) CA2414839C (enExample)
TW (1) TWI271398B (enExample)
WO (1) WO2002002500A1 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069617A1 (en) 2004-12-27 2006-07-06 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Process for transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives, and a novel catalyst system for asymmetric transition metal catalysis
GB2422603A (en) * 2005-01-14 2006-08-02 Phoenix Chemicals Ltd Preparation of 2-substituted-propionic acids and amides by enantioselective hydrogenation
WO2006097314A1 (de) * 2005-03-17 2006-09-21 Basf Aktiengesellschaft Verfahren zur herstellung von optisch aktiven 3-phenylpropionsäurederivaten und folgeprodukte davon
EP1939182A1 (de) * 2006-12-22 2008-07-02 Speedel Experimenta AG Verfahren zur Herstellung von (R oder S)-2-Alkyl-3-heterocyclyl-1-propanolen
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
WO2009007461A1 (en) * 2007-07-11 2009-01-15 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
WO2009007462A1 (en) * 2007-07-11 2009-01-15 Dsm Fine Chemicals Austria Nfg Gmbh & Co. Kg ALPHA-SUBSTITUTED α,β-UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION α,β
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
US7935841B2 (en) 2006-04-21 2011-05-03 Dr. Reddy's Laboratories Limited Bisphospholanes for use as catalysts in asymmetric reactions
WO2011151442A2 (en) 2010-06-04 2011-12-08 Chemo Iberica, S.A. Process for producing aliskiren
US8203005B2 (en) 2009-10-29 2012-06-19 Carbo Design Llc Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
US8445708B2 (en) 2005-10-28 2013-05-21 Reuter Chemischer Apparatebau Kg Process for preparing chiral octenoic acid derivatives
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694251A5 (de) * 1999-07-14 2004-10-15 Eprova Ag Herstellung von Tetrahydropterin und Derivaten.
BR0112128A (pt) * 2000-07-03 2003-05-13 Speedel Pharma Ag Processo para a preparação de (r)-2-alquil-3-fenil-1-propanóis
CA2412910C (en) * 2000-07-03 2010-11-16 Solvias Ag Ferrocenyl diphosphines and their use
DE102005012408A1 (de) * 2005-03-17 2006-09-21 Basf Ag Verfahren zur Herstellung von optisch aktiven 3-Phenylpropionsäurederivaten und Folgeprodukten davon
US9056816B2 (en) 2011-10-25 2015-06-16 Jubilant Life Sciences Limited Process for the preparation of aliskiren

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426216A (en) * 1990-12-28 1995-06-20 Society Nationale Elf Aquitaine Process for the hydrogenation of ethylenically unsaturated organic compounds and ruthenium catalysts for carrying out said process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307232A (en) * 1980-03-21 1981-12-22 E. I. Du Pont De Nemours And Company Preparation of dialkyl- and diarylphosphonoalkanoic acids and substituted acrylic acids
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
JPH09309826A (ja) * 1996-05-22 1997-12-02 Kissei Pharmaceut Co Ltd 糸球体疾患の予防および治療剤
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426216A (en) * 1990-12-28 1995-06-20 Society Nationale Elf Aquitaine Process for the hydrogenation of ethylenically unsaturated organic compounds and ruthenium catalysts for carrying out said process

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
APPLETON, TREVOR D. ET AL: "Rhodium (I) complexes of ferrocenylphosphines as efficient asymmetric catalysts. The structure of Fe(.eta.5-C5H3(P(CMe3)2- 1,3)(.eta.5-C5H3(CHMeNMe2)P(CMe3)2-1,2)", J. ORGANOMET. CHEM. (1985), 279(1-2), 5-21, XP002183785 *
BARTOLI G ET AL: "An efficient procedure for the diastereoselective dehydration of beta-hydroxy carbonyl compounds by CeCl3.7H2O/NaI system", ORGANIC LETTERS, ACS, WASHINGTON, DC, US, vol. 2, no. 13, 1 June 2000 (2000-06-01), pages 1791 - 1793, XP002175161, ISSN: 1523-7060 *
JERRY MARCH: "Advanced organic chemistry, third edition", 1985, WILEY-INTERSCIENCE, NEW YORK, XP002183791 *
KAWANO, HIROYUKI ET AL: "Ruthenium (II)-binap complex-catalyzed asymmetric hydrogenation of unsaturated dicarboxylic acids", TETRAHEDRON LETT. (1987), 28(17), 1905-8, XP002183786 *
MIYANO, SOTARO ET AL: "Axially dissymmetric bis(aminophosphine)s derived from 2,2'-diamino-1,1'-binaphthyl. Synthesis and application to rhodium (I)-catalyzed asymmetric hydrogenations", BULL. CHEM. SOC. JPN. (1984), 57(8), 2171-6, XP002183784 *
SHAO, LIMING ET AL: "Asymmetric synthesis of (R)- and (S)-4-(substituted benzyl)dihydrofuran-2(3H)-ones: an application of the ruthenium -2,2'-bis(diphenylphosphino)-1,1'-binaphthyl complex-catalyzed asymmetric hydrogenation of alkylidenesuccinic acids", J. CHEM. SOC., PERKIN TRANS. 1 (1990), (5), 1441-5, XP002183789 *
UEMURA, TOSHITSUGI ET AL: "Highly Efficient Enantioselective Synthesis of Optically Active Carboxylic Acids by Ru(OCOCH3)2[(S)-H8-BINAP]", J. ORG. CHEM. (1996), 61(16), 5510-5516, XP002183788 *
WEI Y ET AL: "Aldol addition reaction of a lithium ester enolate in the solid state", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 32, no. 12, 18 March 1991 (1991-03-18), pages 1535 - 1538, XP002175158, ISSN: 0040-4039 *
YAMADA T ET AL: "A preparative method of DL-threo-3-isopropylmalic acid and DL-threo-[2-2H]-3-isopropylmalic acid", CHEMISTRY LETTERS, CHEMICAL SOCIETY OF JAPAN. TOKYO, JP, no. 9, September 1987 (1987-09-01), pages 1745 - 1748, XP002175183, ISSN: 0366-7022 *
YAMADA, ISSAKU ET AL: "Asymmetric Hydrogenation of acrylic acid derivatives by novel chiral rhodium-phosphinediamine complex catalysts by selective ligation between two amino units of the ligand and electrostatic interaction", J. CHEM. SOC., PERKIN TRANS. 1 (1990), 1869-73, XP002183790 *
ZHANG, XIAOYONG ET AL: "Highly enantioselective hydrogenation of.alpha.,.beta.-unsaturated carboxylic acid catalyzed by H8-BINAP-Ru(II) complexes", SYNLETT (1994), (7), 501-3, XP002183787 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501193A1 (de) * 2004-12-27 2006-07-15 Dsm Fine Chem Austria Gmbh Verfahen zur übergangsmetall - katalysierten asymmetrischen hydrierung von acrylsäurederivaten
AT501193B1 (de) * 2004-12-27 2007-03-15 Dsm Fine Chem Austria Gmbh Verfahen zur übergangsmetall - katalysierten asymmetrischen hydrierung von acrylsäurederivaten
US7473792B2 (en) 2004-12-27 2009-01-06 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Process for transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives, and a novel catalyst system for asymmetric transition metal catalysis
WO2006069617A1 (en) 2004-12-27 2006-07-06 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Process for transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives, and a novel catalyst system for asymmetric transition metal catalysis
GB2422603A (en) * 2005-01-14 2006-08-02 Phoenix Chemicals Ltd Preparation of 2-substituted-propionic acids and amides by enantioselective hydrogenation
WO2006097314A1 (de) * 2005-03-17 2006-09-21 Basf Aktiengesellschaft Verfahren zur herstellung von optisch aktiven 3-phenylpropionsäurederivaten und folgeprodukte davon
US8450519B2 (en) 2005-10-28 2013-05-28 Reuter Chemischer Apparatebau Kg Process for preparing octenoic acid derivatives
US8445708B2 (en) 2005-10-28 2013-05-21 Reuter Chemischer Apparatebau Kg Process for preparing chiral octenoic acid derivatives
US7935841B2 (en) 2006-04-21 2011-05-03 Dr. Reddy's Laboratories Limited Bisphospholanes for use as catalysts in asymmetric reactions
EP1939182A1 (de) * 2006-12-22 2008-07-02 Speedel Experimenta AG Verfahren zur Herstellung von (R oder S)-2-Alkyl-3-heterocyclyl-1-propanolen
WO2008077917A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Process for preparing (r or s)-2-alkyl-3-heterocyclyl-1-propanols
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
WO2009007462A1 (en) * 2007-07-11 2009-01-15 Dsm Fine Chemicals Austria Nfg Gmbh & Co. Kg ALPHA-SUBSTITUTED α,β-UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION α,β
CN101801903A (zh) * 2007-07-11 2010-08-11 帝斯曼知识产权资产管理有限公司 饱和醛的制备
US8088954B2 (en) 2007-07-11 2012-01-03 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
US8088955B2 (en) 2007-07-11 2012-01-03 Dsm Fine Chemicals Austria Nfg Gmbh & Co. Kg Alpha-substituted α,β-unsaturated E- or Z-aldehydes, use thereof, and processes for their preparation α,β
WO2009007461A1 (en) * 2007-07-11 2009-01-15 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
US8203005B2 (en) 2009-10-29 2012-06-19 Carbo Design Llc Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
WO2011151442A2 (en) 2010-06-04 2011-12-08 Chemo Iberica, S.A. Process for producing aliskiren
WO2011151442A3 (en) * 2010-06-04 2012-05-31 Chemo Iberica, S.A. Process for producing aliskiren
US9346745B2 (en) 2010-06-04 2016-05-24 Chemo Iberica, S.A. Process for producing Aliskiren
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren

Also Published As

Publication number Publication date
US6683206B2 (en) 2004-01-27
AU2001273761A1 (en) 2002-01-14
JP2004502663A (ja) 2004-01-29
BR0112146A (pt) 2003-05-06
AR028783A1 (es) 2003-05-21
CN100482632C (zh) 2009-04-29
EP1296927A1 (en) 2003-04-02
CA2414839A1 (en) 2002-01-10
CA2414839C (en) 2010-02-16
US20030139625A1 (en) 2003-07-24
ATE546425T1 (de) 2012-03-15
TWI271398B (en) 2007-01-21
EP1296927B1 (en) 2012-02-22
CN1440379A (zh) 2003-09-03

Similar Documents

Publication Publication Date Title
EP1296927B1 (en) Preparation of (r)-2-alkyl-3-phenylpropionic acids
EP1296912B1 (en) Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
WO2001092201A1 (fr) Derives substitues d'acide phenylpropionique
NO327958B1 (no) Pregabalin og metode for fremstilling av slike forbindelser
US5256803A (en) Process for the preparation of (2R,3R)-cis)-β-phenylglycidic acid
EP2560493A1 (en) An enantioselective process for cycloalkenyl b-substituted alanines
MXPA01001187A (es) Proceso para la produccion de 3,6-dialquil-5,6-didhidro-4-hidroxi-piran-2-ona.
EP1651657A2 (en) Biphosphine ruthenium complexes with chiral diamine ligands as catalysts
EP1756131A2 (en) Ferrocenyl ligands for homogeneous, enantioselective hydrogenation catalysts
WO2008000815A1 (en) Diphosphine ligands
CN101952242B (zh) 肾素抑制剂的汇集合成和其中有用的中间产物
KR100306964B1 (ko) 광학활성인디아민헥사논유도체의제조방법
EP1658298B1 (en) Phosphorus-containing imidazolines and metal complexes thereof
WO2006075177A1 (en) Process for the manufacture of substituted propionic acids
US7906669B2 (en) Metallocene-based phosphorus chiral phosphines
EP1042270A1 (en) Asymmetric hydrogenation
JP3597890B2 (ja) 3−メトキシプロピオン酸エステル誘導体
WO2007020221A2 (en) Amino-phosphinoalkyl-ferrocenes and their use as ligands in catalysts for asymmetric reactions
CN120794938A (zh) 一种以水为氢源制备手性苯并四氢呋喃类化合物的方法
JPH07316094A (ja) (s)−2−アラルキル−3−クロロプロピオン酸及びその製造方法
JP2003212874A (ja) イソキヌクリジン誘導体の製造方法
HK1093201A1 (zh) 取代的辛酰胺的制备方法
HK1093201B (en) Process for the preparation of substituted octanoyl amides
HK1153189B (en) Convergent synthesis of renin inhibitors and intermediates useful therein
CA2652412A1 (en) Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001940045

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018122310

Country of ref document: CN

Ref document number: 2414839

Country of ref document: CA

Ref document number: 10312855

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001940045

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642